Bellicum Pharmaceuticals Performance
| BLCMDelisted Stock | USD 0.37 0.05 11.90% |
The firm shows a Beta (market volatility) of 0.75, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Bellicum Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Bellicum Pharmaceuticals is expected to be smaller as well. Bellicum Pharmaceuticals right now shows a risk of 0.0%. Please confirm Bellicum Pharmaceuticals total risk alpha, expected short fall, market facilitation index, as well as the relationship between the value at risk and daily balance of power , to decide if Bellicum Pharmaceuticals will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Bellicum Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy fundamental indicators, Bellicum Pharmaceuticals is not utilizing all of its potentials. The newest stock price disarray, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 47.7 M |
Bellicum |
Bellicum Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 37.00 in Bellicum Pharmaceuticals on August 27, 2024 and sell it today you would earn a total of 0.00 from holding Bellicum Pharmaceuticals or generate 0.0% return on investment over 90 days. Bellicum Pharmaceuticals is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than Bellicum, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Bellicum Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Bellicum Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Bellicum Pharmaceuticals, and traders can use it to determine the average amount a Bellicum Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| BLCM |
Based on monthly moving average Bellicum Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Bellicum Pharmaceuticals by adding Bellicum Pharmaceuticals to a well-diversified portfolio.
Bellicum Pharmaceuticals Fundamentals Growth
Bellicum Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Bellicum Pharmaceuticals, and Bellicum Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Bellicum Pink Sheet performance.
| Return On Equity | -1.06 | |||
| Return On Asset | -0.61 | |||
| Operating Margin | (19.69) % | |||
| Current Valuation | (38.62 M) | |||
| Shares Outstanding | 9.5 M | |||
| Price To Earning | 8.50 X | |||
| Price To Book | 1.00 X | |||
| Price To Sales | 5.46 X | |||
| Revenue | 1.5 M | |||
| EBITDA | (28.93 M) | |||
| Cash And Equivalents | 33.17 M | |||
| Cash Per Share | 3.85 X | |||
| Total Debt | 58 K | |||
| Debt To Equity | 0.01 % | |||
| Book Value Per Share | (1.11) X | |||
| Cash Flow From Operations | (25.78 M) | |||
| Earnings Per Share | (1.57) X | |||
| Total Asset | 23.82 M | |||
| Retained Earnings | (575.42 M) | |||
| Current Asset | 96.89 M | |||
| Current Liabilities | 7.45 M | |||
About Bellicum Pharmaceuticals Performance
By examining Bellicum Pharmaceuticals' fundamental ratios, stakeholders can obtain critical insights into Bellicum Pharmaceuticals' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Bellicum Pharmaceuticals is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in Houston, Texas. Bellicum Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 7 people.Things to note about Bellicum Pharmaceuticals performance evaluation
Checking the ongoing alerts about Bellicum Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Bellicum Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Bellicum Pharmaceuticals is not yet fully synchronised with the market data | |
| Bellicum Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Bellicum Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 1.5 M. Net Loss for the year was (24.97 M) with loss before overhead, payroll, taxes, and interest of (17.38 M). | |
| Bellicum Pharmaceuticals currently holds about 33.17 M in cash with (25.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.85, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Bellicum Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Bellicum Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Bellicum Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Bellicum Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Bellicum Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Bellicum Pharmaceuticals' pink sheet. These opinions can provide insight into Bellicum Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Other Consideration for investing in Bellicum Pink Sheet
If you are still planning to invest in Bellicum Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Bellicum Pharmaceuticals' history and understand the potential risks before investing.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |